⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112567 | 0.78 | TSHR (0.36) | — | |
| SCHEMBL1669258 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL4662388 | 0.74 | TSHR (0.33) | — | |
| Hydrochloric Acid SCHEMBL4316309 | 0.74 | TSHR (0.33) | — | |
| Fluoride SCHEMBL22032650 | 0.74 | TSHR (0.33) | — | |
| SCHEMBL6720033 | 0.73 | — | — | |
| SCHEMBL22247230 | 0.72 | TSHR (0.31) | — | |
| SCHEMBL6847218 | 0.71 | — | — | |
| SCHEMBL3246359 | 0.69 | — | — | |
| SCHEMBL4959965 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | claimed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | claimed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | claimed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | claimed |
| EP-3709022-A1 | USES OF LABELED HSP90 INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2020-09-16 | — | — | EP | claimed |
| CN-106083855-B | Purine derivatives useful as Hsp90 inhibitors | 斯隆-凯特林癌症研究院 | 2020-04-10 | — | — | CN | claimed |
| EP-3208615-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-10-09 | — | — | EP | claimed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | claimed |
| EP-3091019-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-04-03 | — | — | EP | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | claimed |
| EP-2486039-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2016-06-01 | — | — | EP | claimed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | claimed |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-12-25 | — | — | US | claimed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | claimed |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-03 | — | — | US | claimed |
| EP-2034839-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | Sloan-Kettering Institute For Cancer Research (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2008005937-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-01-10 | — | — | WO | claimed |
| US-6768024-B1 | CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION | LION BIOSCIENCE AG (DE) | 2004-07-27 | — | — | US | claimed |
| WO-2002012166-A2 | TRIAMINE DERIVATIVE MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | LION BIOSCIENCE AG (DE) | 2002-02-14 | — | — | WO | claimed |